EL7.AI
StocksMedium•17 November 2026•
3 min read

AbbVie Neuroscience Revenue Reaches $3.389 Billion, Up 19.5% in Third Quarter

Key Facts

1Neuroscience portfolio revenue was $3.389 billion in the third quarter of 2026, with operational growth of 19.5%.
2AbbVie raised its 2026 segment revenue outlook by $300 million to $13 billion.
3Vraylar revenue was $1.068 billion and Botox Therapeutic revenue was $1.080 billion in the third quarter.
4Ubrelvy revenue rose 26.9% to $449 million in the third quarter.
5AbbVie shares closed at $294.55 on November 16, 2026.

AbbVie reported neuroscience portfolio revenue of $3.389 billion in the third quarter of 2026, up 19.4% on a reported basis and 19.5% operationally year over year. The company raised its full-year segment revenue outlook by $300 million to $13 billion. Management said the new outlook includes expected annual sales of $4.2 billion each for Vraylar and Botox Therapeutic, and $3.1 billion in total for oral CGRP products. The previous segment estimate was $12.7 billion, according to Zacks. The update puts the neuroscience portfolio at the center of the company’s growth, combining quarterly results with sales estimates for the rest of the year.

Revenue from named products in the portfolio was split in the quarter between $1.080 billion for Botox Therapeutic and $1.068 billion for Vraylar. Sales of Ubrelvy, used to treat migraine, were $449 million, while Qulipta, another migraine treatment, recorded revenue of $398 million. Vyalev revenue was about $286 million. These figures show several products contributing to the segment’s $3.389 billion in revenue, rather than its relying on a single product. Management estimated full-year sales of $4.2 billion each for Botox Therapeutic and Vraylar, with $3.1 billion expected for oral CGRP products.

Quarterly data showed varying growth rates among migraine treatments: Ubrelvy revenue rose 26.9% to $449 million year over year. Qulipta posted operational growth of 38.5%, with revenue of $398 million. AbbVie said Qulipta revenue increased 38.2% on a reported basis, a rate that differs from operational growth after excluding the impact of foreign exchange. The performance of the two products offers a more detailed picture of the components of neuroscience segment growth in the quarter. Management also included total sales of oral CGRP products of $3.1 billion in its full-year outlook.

The neuroscience outlook update was part of a broader revision to AbbVie’s annual guidance: the company raised its 2026 adjusted diluted earnings-per-share outlook range to $13.95–$13.99 from $13.76–$13.96. Chief Executive Robert Michael said the company continued to raise its full-year outlook and increase its quarterly cash dividend, citing “strong outlook and significant momentum.” The company announced an increase in the quarterly cash dividend from $1.73 to $1.82 per share. The higher dividend is scheduled to be paid on February 16, 2027. These decisions link growth in the operating outlook with a change to the cash return announced for shareholders.

In the market’s reaction to the results announcement on October 30, Reuters reported that AbbVie shares rose 1% after third-quarter results topped Wall Street expectations and the company raised its annual earnings outlook. By contrast, Investing.com, citing Reuters, reported that the stock fell 3% before the market opened that day, describing the new annual guidance as largely in line with Wall Street estimates. The stock closed at $294.55 on November 16, according to EL7 data. That closing price is for the November 16 session, while the moves reported by Reuters in the sources relate to the October earnings announcement. The comparison between the two figures is tied to differences in session date and trading time.

AbbVie management said it typically provides its 2027 guidance during the fourth-quarter earnings call. That makes the upcoming earnings call the company’s stated point for announcing its view for the following year. Until then, the updated 2026 outlook reflects management’s estimate of neuroscience segment sales at $13 billion. The announced annual estimates also include sales of $4.2 billion each for Vraylar and Botox Therapeutic, and $3.1 billion for oral CGRP products. These figures remain part of the company’s 2026 outlook, while the timing of guidance for the following year has been set for the fourth-quarter call.

Open on chart